1
|
Abstract
Human health and animal health are closely intertwined. We share hundreds of diseases with animals, and they are vectors for many diseases that assail humans—but, at the same time, they are essential to many treatments and cures. We discuss in this chapter various aspects of intimate relationship between human and animal health, giving examples of the importance of multidisciplinary studies in understanding these connections and the fundamental aspects of strategies for promoting the health and well-being of both groups.
Collapse
|
2
|
Berenbaum F, Grifka J, Brown JP, Zacher J, Moore A, Krammer G, Dutta D, Sloan VS. Efficacy of Lumiracoxib in Osteoarthritis: A Review of Nine Studies. J Int Med Res 2016; 33:21-41. [PMID: 15651713 DOI: 10.1177/147323000503300102] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Lumiracoxib is a cyclooxygenase-2 selective inhibitor in development for the treatment of osteoarthritis (OA), rheumatoid arthritis and acute pain. We reviewed nine clinical studies of 1 − 52 weeks' duration demonstrating the efficacy of lumiracoxib in OA. Male and female patients aged ≥ 18 years with primary OA of the hand, hip or knee received lumiracoxib, placebo or active comparators (diclofenac, celecoxib or rofecoxib). Lumiracoxib provided consistent reductions in OA pain intensity and improvements in the patient's global assessment of disease activity and functional status (assessed using the Western Ontario and McMaster Universities Osteoarthritis Index questionnaire or the Australian/Canadian OA Hand Index). These results were superior to placebo and similar to the active comparators tested. In addition, lumiracoxib was consistently superior to placebo and generally similar to active comparators in terms of the new Outcome Measures in Clinical Trials and Osteoarthritis Research Society International criteria. These were used to provide a single measure of response to treatment, taking into account pain, the patient's global assessment of disease activity and functional status.
Collapse
Affiliation(s)
- F Berenbaum
- Department of Rheumatology, Pierre and Marie Curie University-Saint-Antoine Hospital, Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Abdualkader AM, Ghawi AM, Alaama M, Awang M, Merzouk A. Leech therapeutic applications. Indian J Pharm Sci 2013; 75:127-37. [PMID: 24019559 PMCID: PMC3757849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2012] [Revised: 02/11/2013] [Accepted: 02/20/2013] [Indexed: 12/03/2022] Open
Abstract
Hematophagous animals including leeches have been known to possess biologically active compounds in their secretions, especially in their saliva. The blood-sucking annelids, leeches have been used for therapeutic purposes since the beginning of civilization. Ancient Egyptian, Indian, Greek and Arab physicians used leeches for a wide range of diseases starting from the conventional use for bleeding to systemic ailments, such as skin diseases, nervous system abnormalities, urinary and reproductive system problems, inflammation, and dental problems. Recently, extensive researches on leech saliva unveiled the presence of a variety of bioactive peptides and proteins involving antithrombin (hirudin, bufrudin), antiplatelet (calin, saratin), factor Xa inhibitors (lefaxin), antibacterial (theromacin, theromyzin) and others. Consequently, leech has made a comeback as a new remedy for many chronic and life-threatening abnormalities, such as cardiovascular problems, cancer, metastasis, and infectious diseases. In the 20(th) century, leech therapy has established itself in plastic and microsurgery as a protective tool against venous congestion and served to salvage the replanted digits and flaps. Many clinics for plastic surgery all over the world started to use leeches for cosmetic purposes. Despite the efficacious properties of leech therapy, the safety, and complications of leeching are still controversial.
Collapse
Affiliation(s)
- A. M. Abdualkader
- Department of Pharmaceutical Chemistry, International Islamic University Malaysia, Jalan Istana, 25200 Kuantan, Pahang, Malaysia,Address for correspondence E-mail:
| | - A. M. Ghawi
- Department of Basic Medical Science, Faculty of Pharmacy, International Islamic University Malaysia, Jalan Istana, 25200 Kuantan, Pahang, Malaysia
| | - M. Alaama
- Department of Pharmaceutical Chemistry, International Islamic University Malaysia, Jalan Istana, 25200 Kuantan, Pahang, Malaysia
| | - M. Awang
- Department of Pharmaceutical Chemistry, International Islamic University Malaysia, Jalan Istana, 25200 Kuantan, Pahang, Malaysia
| | - A. Merzouk
- Department of Biopep Solutions Inc., 235-11590 Cambie Road, Richmond, BC V6X 3Z5, Canada
| |
Collapse
|
4
|
Lone AH, Ahmad T, Anwar M, Habib S, Sofi G, Imam H. Leech therapy- a holistic approach of treatment in unani (greeko-arab) medicine. Anc Sci Life 2011; 31:31-5. [PMID: 22736888 PMCID: PMC3377041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The Unani System of Medicine also known as Greeko-Arab medicine, founded by Hippocrates is based on the concept of equilibrium and balance of natural body humours (blood, bile, black bile and phlegm). The imbalance in the quality and quantity of these humours leads to diseases whereas restoration of this balance maintains health of a person. The treatment methodology of diseases is based on four therapeutic modalities viz. Regimental therapy, Dieto-therapy, Pharmacotherapy and surgery. Irsale Alaq (Leech or Hirudo therapy) is one of the most important and widely practised methods of regimental therapy used for local evacuation of morbid humours. It is a procedure of treatment with the use of medicinal leeches. It has been suggested and successfully practised by Greeko-Arab physicians in the management of musculoskeletal diseases, gynaecological disorders, chronic skin diseases, thromboembolic diseases, varicose veins, ENT disorders etc since long. According to Unani doctrine, the efficacy of leech therapy is attributed to the analgesic and resolvent activities of leeches. However, from modern perspective, the saliva of leech contains about 100 pharmacologically active biological substances like Hirudin, hyaluronidase, vasodilators, anesthetics, antibacterial, fibrinases, collagenase etc. These substances are injected into human body while sucking of the blood and are responsible for the analgesic, anti inflammatory and anesthetic effects of leech therapy.
Collapse
Affiliation(s)
- Azad Hussain Lone
- Dept. of Moalajat, National Institute of Unani Medicine, Bangalore - 560091, India
| | | | | | | | | | | |
Collapse
|
5
|
Berna A, Bernier F, Chabrière E, Elias M, Scott K, Suh A. For whom the bell tolls? DING proteins in health and disease. Cell Mol Life Sci 2009; 66:2205-18. [PMID: 19290474 PMCID: PMC11115607 DOI: 10.1007/s00018-009-0006-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2008] [Revised: 02/09/2009] [Accepted: 02/13/2009] [Indexed: 11/29/2022]
Abstract
DING proteins, identified mainly by their eponymous N-terminal sequences, are ubiquitous in living organisms. Amongst bacteria, they are common in pseudomonads, and have been characterised with respect to genetics and structure. They form part of a wider family of phosphate-binding proteins, with emerging roles in phosphate acquisition and pathogenicity. Many DING proteins have been isolated in eukaryotes, in which they have been associated with very diverse biological activities, often in the context of possible signalling roles. Disease states in which DING proteins have been implicated include rheumatoid arthritis, lithiasis, atherosclerosis, some tumours and tumour-associated cachexia, and bacterial and viral adherence. Complete genetic and structural characterisation of eukaryotic DING genes and proteins is still lacking, though the phosphate-binding site seems to be conserved. Whether as bacterial proteins related to bacterial pathogenicity, or as eukaryotic components of biochemical signalling systems, DING proteins require further study.
Collapse
Affiliation(s)
- Anne Berna
- Institut de Biologie Moléculaire des Plantes du CNRS, Institut de Botanique, Université de Strasbourg, 28 rue Goethe, Strasbourg Cedex, France.
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
Leeching has enjoyed a good reputation in the past where it had been used in various ailments from fevers to flatulence. The present day scientists have limited its role and the leeching nowadays is being used only in microsurgeries to relieve the venous congestion. This study was designed to explore the possibility of revival of the leech therapy (leeching) which is still being used traditionally as therapeutic agent in various ailments. Leeching is not the outcome of the medieval period but has been in use during the times when there was no concept of the disease and medicament. The earliest clearly documented record of leeches being used for remedial purpose appears in a painting in an Egyptian Tomb of around 1500 BC. The journey of the leech therapy reached its zenith in 17th and 18th century AD in Europe while as during the Arab era the leeches were used medicinally but only for the bloodletting. During the 17th and 18th century AD there was shortage of leeches in certain European countries due to its rigorous use. During early 20th century AD when germ theory was put forward and medical fraternity believed that every disease has its origin from germs and the era of antibacterial therapy gained a pace, the leech therapy was considered the myth of the past. It was in 1970's that the leech therapy was revived by only limited to the microsurgeries to relieve venous congestions. During the 21st century there were certain studies when the leeches were tried in certain ailments like arthritis etc. and the Food and Drug Authority of USA (FDA) gave permission for sale and use of leeches in USA but limited its use in microsurgeries and plastic surgeries only. The aim of this study was to explore different diseases where the role of leech therapy can be seen and clinical trials can be started in this direction. Although the researchers in Regional Research Institute of Unani Medicine, Srinagar, Kashmir, India working under the aegis of Central Council for Research in Unani Medicine started the clinical trials for leech therapy in frost bite way back in 1999, but there are certain unexplored areas where leech therapy can prove beneficial and need is to take up the studies on other disease on larger sample size.
Collapse
Affiliation(s)
- Younis Munshi
- Regional Research Institute of Unani Medicine, University of Kashmir, Srinagar, J and K, 190006, India
| | | | | | | |
Collapse
|
7
|
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Siebert CH, Stock F, Schneider U. Assessment of leech therapy for knee osteoarthritis: a randomized study. Acta Orthop 2008; 79:235-43. [PMID: 18484250 DOI: 10.1080/17453670710015030] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND AND PURPOSE Symptomatic treatment of osteoarthritis of the knee with leeches is presently undergoing a renaissance. Previous studies have shown methodical weaknesses. In the present study patients were blinded regarding the treatment, and a control group was included to explore possible differences in various subjective clinical scores and intake of pain medication over time between leech therapy and placebo control. PATIENTS AND METHODS 113 patients with advanced osteoarthritis of the knee were included. The patients were randomized to a single treatment group, group I (single leech application, n = 38), a double treatment group, group II (double application, n = 35), and a control group (n = 40). The second treatment in group II took place after an interval of 4 weeks. The treatment in the control group was simulated with the help of an "artificial leech". Results were documented with the KOOS and WOMAC scores and also a visual analog scale (VAS) for pain. Changes in the use of pain medication were monitored over 26 weeks. RESULTS An improvement in KOOS and WOMAC scores, and also in VAS, was found in all 3 groups following treatment. These improvements were statistically significant for treatment groups I and II during the complete follow-up period. The reduction in individual requirements for pain medication was also statistically significant. The greatest improvement was seen in the group treated twice with the leeches, with a long-term reduction of joint stiffness and improved function in the activities of daily living. INTERPRETATION Leech therapy can reduce symptoms caused by osteoarthritis. Repeated use of the leeches appears to improve the long-term results. We have not determined whether the positive outcome of the leech therapy is caused by active substances released during the leeching, the placebo effect, or the high expectations placed on this unusual treatment form.
Collapse
Affiliation(s)
- Stefan Andereya
- Department of Orthopaedic Surgery, Univresity Hospital of the RWTH Aachen, Annastift Hanover, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Bannwarth B, Bérenbaum F. Lumiracoxib in the management of osteoarthritis and acute pain. Expert Opin Pharmacother 2007; 8:1551-64. [PMID: 17661736 DOI: 10.1517/14656566.8.10.1551] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Lumiracoxib is a highly selective COX-2 inhibitor with a novel chemical structure and a relatively short plasma half-life. It has been approved in > 40 countries for the symptomatic treatment of osteoarthritis and/or acute pain related to primary dysmenorrhoea and dental or orthopaedic surgery. In these conditions, lumiracoxib has proved to be as effective as standard doses of conventional NSAIDs and other COX-2 selective inhibitors (coxibs). According to the Therapeutic Arthritis Research Gastrointestinal Trial, which enrolled 18,325 patients with osteoarthritis, lumiracoxib 400 mg/day (four times its recommended dosage) was associated with a significant decrease in the risk of ulcer complications compared with naproxen 1000 mg/day and ibuprofen 2400 mg/day, at least in the population not taking low-dose aspirin. The atherothrombotic potential of NSAIDs, especially coxibs, has been much debated. In this respect, available data do not suggest that lumiracoxib may be associated with an increased hazard of cardiovascular events compared with non-selective NSAIDs. Finally, lumiracoxib may be an effective and safe drug provided both physicians and patients will comply with its approved indications and contraindications.
Collapse
Affiliation(s)
- Bernard Bannwarth
- Groupe Hospitalier Pellegrin, Service de Rhumatologie, Bordeaux Cedex, France.
| | | |
Collapse
|
9
|
Hu W, Criswell MH, Ottlecz A, Cornell TL, Danis RP, Lambrou GN, Ciulla TA. ORAL ADMINISTRATION OF LUMIRACOXIB REDUCES CHOROIDAL NEOVASCULAR MEMBRANE DEVELOPMENT IN THE RAT LASER-TRAUMA MODEL. Retina 2005; 25:1054-64. [PMID: 16340537 DOI: 10.1097/00006982-200512000-00015] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
PURPOSE To determine whether lumiracoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor that exhibits anti-inflammatory and antiangiogenic properties, can inhibit experimental choroidal neovascular membrane (CNVM) development induced by focal laser trauma in a well-characterized Brown Norway rat CNVM model. METHODS Over a 35-day period, 24 rats received daily oral gavage dosages of 20 mg/kg lumiracoxib in a 0.5% (w/v) suspension of sodium carboxymethylcellulose (CMC), while a control group received the 0.5% CMC suspension only. After 7 days, eight laser photocoagulation sites were placed concentrically around the optic disk to induce CNVMs. Thirty-five days later, fundus photography and fluorescein angiography (FA) were performed and eyes were processed for histopathologic analysis. RESULTS Masked FA grading of lesion sites revealed a small, but statistically significant difference (P<0.0001) in late stage staining intensity and leakage between the mean group scores of treated (1.4) and control (1.7) eyes. Histopathologic analysis demonstrated that the mean CNVM thickness +/- SD of 38 +/-19 microm (n=24 eyes, 175 photocoagulation sites) in the lumiracoxib-treated animals was reduced by 30% (P<0.001) compared to the CNVM mean thickness+/- SD of 54+/- 20 microm (n=24 eyes, 171 photocoagulation sites) in the control animals. CONCLUSION Systemic administration of the selective COX-2 inhibitor lumiracoxib results in a partial but significant reduction in CNVM development in the rat laser-trauma model and thus may be clinically beneficial as a potential inhibitor of CNVM formation in exudative age-related macular degeneration.
Collapse
Affiliation(s)
- Wenzheng Hu
- Retina Service Research Laboratories, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
Scott G, Vinluan Reynolds C, Milosavljev S, Langholff W, Shenouda M, Rordorf C. Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. Clin Pharmacokinet 2004; 43:341-8. [PMID: 15080766 DOI: 10.2165/00003088-200443050-00006] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
OBJECTIVE To evaluate the effects of multiple doses of omeprazole and of a single dose of an aluminium hydroxide/magnesium hydroxide (Al/Mg) antacid on the single-dose plasma pharmacokinetics of lumiracoxib. STUDY DESIGN Open-label, randomised, three-period, crossover study. POPULATION STUDIED Healthy subjects aged 18-65 years. METHODS Fourteen subjects who met eligibility criteria were each administered three treatments in random order: (A) lumiracoxib 400 mg as a single oral dose; (B) oral omeprazole 20 mg once daily for 4 consecutive days, then lumiracoxib 400 mg as a single oral dose just prior to oral omeprazole 20 mg on day 5; and (C) lumiracoxib 400 mg as a single oral dose immediately prior to a 20 mL dose of Al/Mg antacid (magnesium hydroxide 800 mg and aluminium hydroxide 900 mg). The interval between each lumiracoxib dose was 7 days. Analysis of variance was performed to determine whether lumiracoxib alone differed from lumiracoxib plus omeprazole or from lumiracoxib plus Al/Mg antacid for overall exposure (area under the concentration-time curve from zero to infinity [AUC( infinity )]) and peak concentration (C(max)), with treatment sequence, subject, period and treatment as factors. Ratios of geometric means between lumiracoxib plus omeprazole and lumiracoxib plus Al/Mg antacid to lumiracoxib alone (reference) were calculated for AUC( infinity ) and C(max). If the mean ratios, with 90% CIs, fell within the interval 0.80-1.25, the treatments were considered equivalent. RESULTS Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively. AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg. h/L). All ratios of geometric means with 90% CIs fell within the interval used for establishing bioequivalence, except for the C(max) comparison between lumiracoxib plus Al/Mg antacid and lumiracoxib alone, which was 1.11 (0.95, 1.31). CONCLUSIONS Coadministration of lumiracoxib with omeprazole or with an Al/Mg antacid had no clinically significant effect on lumiracoxib single-dose plasma pharmacokinetics. Lumiracoxib can, therefore, be administered concurrently with either of these agents without need for lumiracoxib dosage alteration.
Collapse
Affiliation(s)
- Graham Scott
- Department of Exploratory Clinical Development, Novartis Pharmaceuticals, Horsham, UK.
| | | | | | | | | | | |
Collapse
|